Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

197.44
2,981,329

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $197.40 -0.04 (-0.02%) 6:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.

    Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

    Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.

      HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

      Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

        DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?

        Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.

          AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

          AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

            Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?

            Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.

              Debapriya Chakraborty headshot

              AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up

              AbbVie's (ABBV) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared to year ago figure.

                What's in the Cards for Inogen (INGN) This Earnings Season?

                Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.

                  Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

                  Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

                    Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

                    Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

                      Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

                      Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

                        What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?

                        Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.

                          Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?

                          Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.

                            What Lies Ahead for Vice ETFs?

                            Vice ETFs, which aim to profit from companies involved in alcohol, tobacco or gambling, are gathering steam.

                              Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                              Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

                                Sweta Killa headshot

                                Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

                                Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

                                  Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?

                                  Solid prospects in Global Industrial, Global Energy and Global Institutional segments are likely to drive Ecolab's (ECL) Q1 earnings.

                                    Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

                                    Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

                                      J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

                                      Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

                                        Roche Hemophilia Drug Gets Breakthrough Therapy Designation

                                        The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

                                          The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

                                          The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

                                            5 Drug Stocks Poised to Surpass on Earnings This Quarter

                                            The outlook for the upcoming first-quarter results looks bright.

                                              J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

                                              J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

                                                Shire Sells Oncology Unit Ahead of Takeda's Potential Offer

                                                Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.

                                                  Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                                                  The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.